<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782245</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1135</org_study_id>
    <secondary_id>2020-005713-40</secondary_id>
    <nct_id>NCT04782245</nct_id>
  </id_info>
  <brief_title>Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List</brief_title>
  <acronym>ARCADIA-HF</acronym>
  <official_title>Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List: a Multicenter, Double-blind, Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the DAPA-HF trial, the use of dapagliflozin, an inhibitor of sodium-glucose cotransporter&#xD;
      2 (SGLT2), reduced significantly the risk of worsening heart failure or death from&#xD;
      cardiovascular causes compared to placebo among patients with heart failure (HF) and a&#xD;
      reduced ejection fraction. This new drug offers a very potent and interesting therapeutic&#xD;
      pathway since it reduces clinical congestion, it preserves glomerular renal function, does&#xD;
      not appear to cause symptomatic clinical hypotension and improves symptoms and quality of&#xD;
      life compared to placebo.&#xD;
&#xD;
      Advanced heart failure patients with reduced ejection fraction represent a small and severe&#xD;
      subgroup of heart failure of patients with frequent worsening heart failure events and high&#xD;
      rates of death. The effect of dapagliflozin in this subgroup of patients was not assessed in&#xD;
      the DAPA-HF study. The therapeutic profile of SGLT2 inhibitors appears to be of high&#xD;
      interest, since this group of patients has a poor tolerance to usual heart failure drugs,&#xD;
      frequent worsening renal function and congestive symptoms persistence with poor quality of&#xD;
      life scores.&#xD;
&#xD;
      Soluble urokinase-type plasminogen activator receptor (suPAR) is a signaling glycoprotein&#xD;
      considered to be involved in the pathogenesis of kidney disease. It is associated with the&#xD;
      risk of acute kidney injury in different clinical and experimental situation. It is also a&#xD;
      new validated biomarker predictive of adverse clinical outcome in heart failure patients.&#xD;
      This biomarker allows a better risk stratification in heart failure patients after adjustment&#xD;
      for Nt-proBNP.&#xD;
&#xD;
      As a useful biomarker implicated in both heart failure and acute kidney injury, suPAR seems&#xD;
      to be an interesting biomarker to assess cardio-renal benefits of dapagliflozin.&#xD;
&#xD;
      The aim of this study is to investigate if a treatment by dapagliflozin reduces significantly&#xD;
      suPAR compared to placebo in a population of advanced heart failure patients, candidates to&#xD;
      heart transplantation. The effect of dapagliflozin compared to placebo will also be assessed&#xD;
      on other secondary heart failure outcomes in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of suPAR (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VO2 max assessment</measure>
    <time_frame>6 months</time_frame>
    <description>VO2 max assessment to evaluate the functional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output assessed by right heart catheterization</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary capillary wedge pressure assessed by right heart catheterization</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary artery systolic and mean pressure assessed by right heart catheterization</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean pressure assessed by right heart catheterization</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right atrial pressure assessed by right heart catheterization</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Function assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic diameter assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end systolic volume assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitral regurgitation grade assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left atrial volume assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nt-proBNP level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>End-stage Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment group Daplagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.</description>
    <arm_group_label>Treatment group Daplagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has signed informed consent form&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. NYHA class ≥3&#xD;
&#xD;
          4. LVEF ≤ 35%&#xD;
&#xD;
          5. On optimal medical management (OMM) based on current heart failure practice guidelines&#xD;
             at maximal tolerated dose for at least 30 days&#xD;
&#xD;
          6. On waiting list for heart transplantation after multidisciplinary Heart Team decision,&#xD;
             with anticipated access to heart transplant ≥ 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Priority patient on waiting list for heart transplantation&#xD;
&#xD;
          2. Etiology of heart failure due to or associated with uncorrected thyroid disease,&#xD;
             obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive&#xD;
             cardiomyopathy&#xD;
&#xD;
          3. Inotrope dependent, existence of ongoing mechanical circulatory support&#xD;
&#xD;
          4. Current acute decompensated HF or hospitalization due to decompensated HF &lt;30 days&#xD;
             prior to the enrolment&#xD;
&#xD;
          5. History of any organ transplant or prior implantation of a ventricular assistance&#xD;
             device (VAD) or similar device, or implantation expected after randomization&#xD;
&#xD;
          6. Presence of an active, uncontrolled infection&#xD;
&#xD;
          7. Any recent interventional procedure likely to improve symptoms and heart failure&#xD;
             status (coronary revascularization, percutaneous mitral valve intervention, cardiac&#xD;
             resynchronization therapy) &lt; 60 days&#xD;
&#xD;
          8. Glomerular filtration rate &lt; 30 ml/min/1.73 m2, according to CKD-EPI formula&#xD;
&#xD;
          9. Unstable or rapidly progressing renal disease&#xD;
&#xD;
         10. Patients with severe hepatic impairment (Child-Pugh class C)&#xD;
&#xD;
         11. Chronic treatment with dapagliflozin or other SGLT2 inhibitors&#xD;
&#xD;
         12. Patient with known history of severe drug intolerance to dapagliflozin or any&#xD;
             excipients of the dapagliflozin (galactose, lactase)&#xD;
&#xD;
         13. Type 1 diabetes mellitus&#xD;
&#xD;
         14. Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or extraction of study drug at investigators' discretion&#xD;
&#xD;
         15. Participation in another clinical interventional trial&#xD;
&#xD;
         16. Any condition other than heart failure that could limit survival to less than 24&#xD;
             months&#xD;
&#xD;
         17. Positive pregnancy test if of childbearing potential or refusal to use adequate&#xD;
             contraception or women breast-feeding&#xD;
&#xD;
         18. Patients with any legal protection measure&#xD;
&#xD;
         19. Patients without any health coverage&#xD;
&#xD;
         20. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychological&#xD;
             issues that are likely to impair compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume BAUDRY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume BAUDRY, Dr</last_name>
    <phone>4 72 11 90 36</phone>
    <phone_ext>+33</phone_ext>
    <email>guillaume.baudry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naoual EL JONHY</last_name>
    <email>naoual.el-jonhy@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Pneumologique et Cardiovasculaire Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume Baudry, Dr</last_name>
      <phone>4 72 11 90 36</phone>
      <phone_ext>+33</phone_ext>
      <email>guillaume.baudry@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End-stage heart failure,</keyword>
  <keyword>Cardio-renal syndrome</keyword>
  <keyword>Dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

